CHE
Chemed Corp
$488.59
-1.87 (-0.38%)
At close · Jul 10
Market Cap
$6.49B
Shares
13,274,104
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$488.59
Open$491.29
Day$482.60–493.47
52W$365.21–493.47
Avg vol 30d198K
Short int564K · 4.3% float · 2.3d
Short vol69%
Last earningsApr 23, 2026
DataJan 2020–Jul 2026
Filing10-Q · Apr 28
Up next
Next earnings call
Jul 26, 2026
Est · unconfirmed
· in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 28, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+13%
above
Price vs 50-day avg
+11%
above
RSI (14)
69
neutral
MACD trend
Positive
52-week position
96%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+12%
trailing
6-month return
+7%
trailing
YTD return
+14%
this year
Relative strength
−2%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $441 › 200d $431 — 50d above 200d
Institutional flow
Accumulating
15 of 489 funds reported for Jun 30 · net +1.5K sh shares · +3 new
Insider flow
Distributing
Net -$1.7M over 90 days · 100% sells
Short interest
Falling
4.25% of float · ▼ -6.3% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
489 holders — mid 3-yr range
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
+4%
Y/Y
EPS growth
−8%
Y/Y
Free cash flow
$325.5M
Valuation
P/E 26.7
in line
Buyback
$229.6M
remaining
Balance sheet
$23.0M
net debt
Quant / Vol
risk profile
Volatility
32%
annualized · 1-yr
Max drawdown
−23%
past year
ATR
2.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+13%
Bullish
Price vs 50-day avg
+11%
Bullish
RSI (14)
69
Neutral
MACD trend
Positive
Bullish
52-week position
96%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $441 › 200d $431 — 50d above 200d
Institutional flow
Accumulating
15 of 489 funds reported for Jun 30 · net +1.5K sh shares · +3 new
Insider flow
Distributing
Net -$1.7M over 90 days · 100% sells
Short interest
Falling
4.25% of float · ▼ -6.3% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
489 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $365
Now $489 · 96%
52-wk high $493
vs 200-day avg +13%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (Roto-Rooter) non-GAAP | $53.5M | first quarter 2026 | — |
| Adjusted EBITDA margin (Roto-Rooter) non-GAAP | 22.5% | first quarter 2026 | — |
| Adjusted EBITDA margin, excluding Medicare Cap (VITAS) non-GAAP | 16.8% | first quarter 2026 | — |
| Adjusted EBITDA, excluding Medicare Cap (VITAS) non-GAAP | $70.8M | first quarter 2026 | — |
| Admissions | 19,394 | first quarter 2026 | — |
|
|
|||
| Average revenue per patient per day (VITAS) | $210.62 | first quarter 2026 | — |
| Admissions from all other preadmission locations (Florida combined program) growth | 8.4% | Q1 2026 call | — |
| Average daily census (VITAS) | 22,723 | Q1 2026 call | — |
| Average revenue per day (VITAS) | $210.62 | Q1 2026 call | — |
| High-acuity days of care as a percent of total days of care (VITAS) | 2.3% | Q1 2026 call | — |
| Home-based patient admissions growth (VITAS) | 2% | Q1 2026 call | — |
| Hospital admissions as a percent of total admissions (Florida combined program) | 43.8% | Q1 2026 call | — |
| Hospital-directed admissions growth (VITAS) | 13.6% | Q1 2026 call | — |
| Paid leads as a percent of total leads (Roto-Rooter) | 53.4% | Q1 2026 call | — |
| Paid leads growth (Roto-Rooter) | 18.7% | Q1 2026 call | — |
| Roto-Rooter gross margin | 51% | Q1 2026 call | — |
| Total leads growth (Roto-Rooter) | 3.3% | Q1 2026 call | — |
| VITAS admissions | 19,394 | Q1 2026 call | — |
| Adjusted Diluted EPS non-GAAP | $6.42 | Q4 2025 | — |
| Adjusted EBITDA non-GAAP | $47.5M | Q4 2025 | — |
| Adjusted EBITDA margin non-GAAP | 21.5% | Q4 2025 | — |
| Adjusted EBITDA margin, excluding Medicare Cap non-GAAP | 21.7% | Q4 2025 | — |
| Adjusted EBITDA, excluding Medicare Cap non-GAAP | $91.6M | Q4 2025 | — |
| Average revenue per patient per day | $208.01 | Q4 2025 | — |
| Reimbursement for high acuity care | $1,153.55 | Q4 2025 | — |
| Reimbursement for routine home care | $187.19 | Q4 2025 | — |
| Revenue from independent contractors | $16.7M | Q4 2025 | — |
| Roto-Rooter branch commercial revenue | $55.2M | Q4 2025 | — |
| Roto-Rooter branch residential revenue | $155.6M | Q4 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CHE
this stock
Chemed Corp
|
$6.49B | +14.3% | +4.1% | 26.7 | 4.3% |
|
HCA
HCA Healthcare, Inc.
|
$90.20B | -12.8% | +7.1% | 14.0 | 2.4% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$27.44B | -15.0% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$17.59B | +2.8% | -2.3% | 10.6 | 4.3% |
|
DVA
Davita Inc.
|
$14.95B | +104.9% | +6.5% | 21.7 | 7.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CHE | -0.2% | +12.5% | +6.6% | +4.9% | +14.3% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -1.6% | +8.4% | -2.5% | +3.8% | +3.6% |
Capital returns
Latest dividend
$0.60
/ share · ex May 28, 2026
Paid (TTM)
$2.40
/ share · 4 payouts
Dividend yield (TTM, derived)
0.49%
Buyback program
· as of Mar 31, 2026
Authorized
$300.00M
Spent (derived)
$70.40M
Remaining
$229.60M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.